欧洲机构建议批准Sarclisa治疗欧盟病人的多眼瘤。 European agency recommends approval for Sarclisa to treat multiple myeloma in EU patients.

欧洲医药机构委员会建议Sarclisa在欧盟批准治疗无资格移植的病人的多种间皮瘤。 The European Medicines Agency's committee has recommended Sarclisa for approval in the EU to treat multiple myeloma in patients ineligible for transplants. 根据IMROZ第3阶段研究,Sarclisa与VRd一起改善了与VRd相比的无进展生存。 Based on the IMROZ phase 3 study, Sarclisa combined with VRd improved progression-free survival compared to VRd alone. 如果获得批准,Sarclisa将成为欧盟首例用于这种用途的反CD38疗法。 If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this use. 这项治疗已经在美国和50多个国家得到批准。 The treatment is already approved in the US and over 50 other countries.